Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Home Gains Buoy Cipla In Q1 But US Momentum Pivotal

Executive Summary

A strong run on home turf lifted Cipla in Q1, but US momentum with differentiated launches is what investors are keeping a sharp eye on. A China play in the respiratory space is also on the cards for the Indian firm.

Related Content

Cipla Warns Of Tough 2H - Pressure On Tender Business, Sanctions-Related Volatility
India Pharma Firms Eye China, Dr Reddy’s Sees ‘Great Opportunity’ There
Amid Pharma ‘Landmarks’ Cipla Develops Tenofovir Prodrug
Chindia Generics: A Dream or Reality?
Chindia Generics: A Dream or Reality?
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Cipla Sounds The Bugle On US Respiratory Ambition
Roche Primes New Push Via Cipla For Avastin, Actemra In India
Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts